Cleared Traditional

K182784 - MUTYH-Associated Polyposis (MAP)

K182784 is an FDA 510(k) clearance for MUTYH-Associated Polyposis (MAP), manufactured by 23AndMe, Inc.. The device is a Class 2 Medical Genetics device with product code QAZ cleared through the Traditional 510(k) pathway after a 109-day FDA review.

K182784 · 23AndMe, Inc. · Medical Genetics device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2019
Decision
109d
Days
Class 2
Risk

K182784 is an FDA 510(k) clearance for the MUTYH-Associated Polyposis (MAP). Classified as Cancer Predisposition Risk Assessment System (product code QAZ), Class II - Special Controls.

Submitted by 23AndMe, Inc. (Mountain View, US). The FDA issued a Cleared decision on January 18, 2019 after a review of 109 days - within the typical 510(k) review window.

This device falls under the Medical Genetics FDA review panel, regulated under 21 CFR 866.6090 - the FDA medical genetics device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Medical Genetics review framework, consistent with the majority of Class II 510(k) submissions.

View all 23AndMe, Inc. devices

FDA 510(k) Submission Details - K182784

510(k) Number K182784 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 01, 2018
Decision Date January 18, 2019
Days to Decision 109 days
Submission Type Traditional
Review Panel Medical Genetics (MG)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
288d faster than avg
Panel avg: 397d · This submission: 109d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

QAZ Device Classification - Class 2, Special Controls

Product Code QAZ Cancer Predisposition Risk Assessment System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.6090
Definition A Qualitative In Vitro Molecular Diagnostic System Used For The Detection Of Select Variants In Specified Cancer-related Genes. The Device Is Intended To Be Used On Genomic Dna Isolated From Human Specimens Collected By The User. The Results Of The Test Provide Users With A Genetic Health Risk Assessment For Developing Certain Cancers. The Test May Not Include All Variants Associated With A Predisposition Of Developing Cancer And Is Not Intended To Describe A Person’s Overall Risk Of Developing Any Type Of Cancer Nor To Aid In Determination Of Treatment Or Act As A Substitute For Recommended Cancer Screenings Or Appropriate Follow-up. The Device Is For Over-the-counter Use.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Medical Genetics devices follow this clearance model.

Regulatory Peers - QAZ Cancer Predisposition Risk Assessment System

Devices cleared under the same product code (QAZ) and FDA review panel - the closest regulatory comparables to K182784.
23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
K223597 · 23AndMe, Inc. · Aug 2023
23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)
K211499 · 23AndMe, Inc. · Jan 2022
23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
DEN170046 · 23AndMe, Inc. · Mar 2018